We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Max Planck Institute and Cellomics Announce Collaboration for High Content Screening Development

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Max Planck Institute and Cellomics Announce Collaboration for High Content Screening Development"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
The Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), located in Dresden, Germany, and Cellomics, a unit of Fisher Biosciences, recently announced a joint collaboration in the field of High Content Screening (HCS). The institute serves as a hub for numerous academic-industry collaborations in the field of HCS for drug discovery.

Cellomics provides a unique cell-based platform for its global clients in pharmaceutical, biotechnology, and academic institutions.

"We have always put a great effort in building bridges between academia and the industry," says Dr. Ivan C. Baines, Scientific Coordinator and Director of Services and Facilities at MPI-CBG.

"Working with a leader in a given technology provides unique opportunities to make new discoveries. Cellomics is a leader in high content screening instruments and applications - an area where we are very active having recently established a major assay development and screening facility. We anticipate a highly productive collaboration and are delighted to be working with Cellomics."

According to Daniel J. Calvo, President of Cellomics, the collaboration objectives include a mix of applications and new product development, as well as establishing a key demonstration center for Europe.  "Max Planck is a perfect partner for us," stated Calvo.

"They have tremendous experience and capabilities in this area and their strong ties to key academic centers across Europe are a real plus.  This collaboration will provide valuable input to help drive the development of our product and applications portfolio for the growing academic market."

As part of the Agreement, MPI-MCBG has purchased the Cellomics' ArrayScan® VTI HCS Reader along with its complete portfolio of BioApplications and HCi™ informatics software.